Source: CV Sciences, Inc.
CV Sciences, Inc. (OTCBB: CVSI)
(the "Company", "CV Sciences", "our" or "we"), today provided comments
from its management with regards to the MLB's recent ban on smokeless
chewing tobacco for new players.
Beginning this upcoming season,
cities that include San Francisco, Boston, and Los Angeles will ban
smokeless tobacco in the big-league ballparks and other sports venues.
The city councils of Chicago and New York recently approved similar
prohibitions on smokeless tobacco for Wrigley Field, U.S. Cellular
Field, Citi Field and Yankee Stadium.
Michael Mona, Jr.,
President and CEO of CV Sciences commented, "We applaud baseball's new
labor agreement that prohibits all new players from using smokeless
tobacco, like chew, dip and snuff. The recent death of former San Diego
Padres Hall of Famer Tony Gwynn has highlighted the seriousness of the
issue. Mr. Gwynn attributed his long struggle with salivary gland cancer
directly to his many years of chewing tobacco. Curt Schilling, former
Boston Red Sox pitcher revealed his diagnosis of oral cancer which he
stated was 'without a doubt, unquestionably' due to decades of chewing
tobacco. We strongly believe that highlighting these examples are
critical as we at CV Sciences are addressing a massive unmet medical
need in the treatment of smokeless tobacco addiction. Currently, there
are no FDA-approved drugs to treat this widespread and deadly addiction.
Our lead drug candidate, CVSI-007, is aimed at addressing this huge
unmet need. We estimate that the current treatment market in the U.S.
alone is greater than $2 billion."
An article on baseballs' decision can be found here: http://tobaccofreebaseball.org/content/press-release-12_1_2016/
About CV Sciences, Inc.
CV Sciences, Inc. (OTCBB: CVSI)
operates two distinct business segments: a drug development division
focused on developing and commercializing novel therapeutics utilizing
synthetic CBD; and, a consumer product division in manufacturing,
marketing and selling plant-based CBD products to a range of market
sectors. CV Sciences, Inc. has primary offices and facilities in Las
Vegas, Nevada and San Diego, California. Additional information is
available from OTCMarkets.com or by visiting www.cvsciences.com.
No comments:
Post a Comment